Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 20/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25293858 | 0.89 | CTPS1 (0.51) | CTPS1 | |
| SCHEMBL22924884 | 0.88 | CTPS1 (0.61) | CTPS1 | |
| SCHEMBL21373755 | 0.88 | CTPS1 (0.50) | CTPS1 | |
| Potassium Ion SCHEMBL21373735 | 0.86 | CTPS1 (0.59) | CTPS1 | |
| SCHEMBL21373830 | 0.85 | CTPS1 (0.57) | CTPS1 | |
| SCHEMBL21381572 | 0.83 | CTPS1 (0.48) | CTPS1 | |
| SCHEMBL22924763 | 0.81 | CTPS1 (0.50) | CTPS1 | |
| SCHEMBL21382338 | 0.81 | CTPS1 (0.53) | CTPS1 | |
| Potassium SCHEMBL30882879 | 0.81 | CTPS1 (0.49) | CTPS1 | |
| SCHEMBL29228050 | 0.81 | CTPS1 (0.49) | CTPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282756-A1 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | STEP PHARMA S.A.S. (FR) | 2025-09-11 | — | — | US | disclosed |
| US-12371419-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | STEP PHARMA S.A.S. (FR) | 2025-07-29 | — | — | US | disclosed |
| US-20250066324-A1 | AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2025-02-27 | — | — | US | disclosed |
| US-11987573-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | STEP PHARMA S.A.S. (FR) | 2024-05-21 | — | — | US | disclosed |
| CN-111868051-B | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-3768674-B1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S A S (FR) | 2024-01-03 | — | — | EP | disclosed |
| CN-112839938-B | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20210387965-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2021-12-16 | — | — | US | disclosed |
| US-20210387965-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2021-12-16 | — | — | US | disclosed |
| CN-112839938-A | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| EP-3768674-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. (FR) | 2021-01-27 | — | — | EP | disclosed |
| CN-111868051-A | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| EP-3543232-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. (FR) | 2019-09-25 | — | — | EP | disclosed |
| EP-3543232-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. (FR) | 2019-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371419-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | CTPS1, CTPS2, TYMS | CTPS1 1/4885 |
| US-20250282756-A1 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | CTPS1, CTPS2, TYMS | CTPS1 1/4885 |
| US-20250066324-A1 | AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORS | CTPS1, CTPS2, TYMS | CTPS1 1/4885 |
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885 |
| US-20210387965-A1 | Compounds | CYP1A1, UGT1A1, CYP1B1 | CTPS1 2704/4885 |
| US-11987573-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | CTPS1, CTPS2, TYMS | CTPS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.